Wednesday, June 1, 2016

Maxim likes ContraVir merger with Ciclofilin

Maxim likes ContraVir merger with Ciclofilin

May 31, 2016 by · Leave a Comment 

Tweet The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group analyst Jason Kolbert. The mechanism of action of Ciclofilin’s antiviral asset, CPI-431-32, should be complementary to ContraVir’s CMX157 by inhibiting distinct critical steps in the viral […]

ContraVir Pharma to merge with Ciclofilin Pharma

ContraVir Pharma to merge with Ciclofilin Pharma

May 31, 2016 by · Leave a Comment 

Tweet ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals. Under the accord, ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments, which will be allocated among the holders of Ciclofilin common stock. The milestone payments will consist of up […]

ARIAD Pharma initiates Phase 1/2 trial in NSCLC

ARIAD Pharma initiates Phase 1/2 trial in NSCLC

May 31, 2016 by · Leave a Comment 

Tweet ARIAD Pharmaceuticals (NASDAQ:ARIA) has initiated a Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2. AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition […]

Lipocine advancing pipeline, PDUFA for oral TRT

Lipocine advancing pipeline, PDUFA for oral TRT

May 31, 2016 by · Leave a Comment 

Tweet With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing towards Phase 3 ready status this year. “We have a robust pipeline with a number of key milestones in 2016 besides the decision on […]

Roth ups Titan Pharma price target to $10

Roth ups Titan Pharma price target to $10

May 30, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid addiction. The stock closed at $7.07 on Friday. “The hook here is forced compliance,” writes analyst Scott Henry. “The implant removes the risk of noncompliant […]

Roth resumes coverage of Fibrocell at buy

Roth resumes coverage of Fibrocell at buy

May 24, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target diseases of the skin, connective tissue and joints. The technology can take advantage of the inherent properties of fibroblasts, but also […]

Vital enrolls first subject in Phase 3 ELAD trial

Vital enrolls first subject in Phase 3 ELAD trial

May 23, 2016 by · Leave a Comment 

Tweet Vital Therapies (NASDAQ:VTL) has enrolled the first subject in its Phase 3 trial designated, VTL-308, to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. ELAD is an extracorporeal human allogeneic cellular liver therapy. The trial is intended to enroll a minimum of 150 subjects, who will be randomized one-to-one to either […]

Roth adjusts DelMar Pharma price target to $12

Roth adjusts DelMar Pharma price target to $12

May 23, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday. Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a […]

Anavex gets orphan drug status in Rett syndrome

Anavex gets orphan drug status in Rett syndrome

May 20, 2016 by · Leave a Comment 

Tweet The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome. In a statement, Christopher Missling, president and CEO, said orphan drug designation marks the first U.S. movement for ANAVEX 2-73. Rett syndrome is a devastating disease occurring in early childhood and almost exclusively in […]

Roth ups Celator Pharma price target to $26

Roth ups Celator Pharma price target to $26

May 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday “This is an important next step for Vyxeos on the path to what we believe is likely approval,” […]

Next Page »

Email Newsletters with Constant Contact
Google+